The mean cost increased to $104,071 955% CI: $102,373 - $105,770) per patient when one includes abiraterone initiation prior to docetaxel therapy.
Unadjusted mean and median costs increased with agitation score (p≤0.001; table 2).
For families with both spouses working, or teachers supplementing their income with second or even third jobs, the change would mean cost increases.
Therefore, in this health economy analysis, we sought to further investigate this mean cost increase of €1,110.00 per patient by Early PN.
In contrast, in patients who had a prolonged ICU stay without a new infection, the mean cost increase by Early PN was €2,917.00.
However, the mean cost increase of €650 per treatment day can be counterbalanced by the time saved by nurses and intensivists, and by a potential beneficial effect on outcome.
In this country, mean hospitalization costs increased, whereas in all other countries, mean hospitalization costs decreased (absolutely and as a proportion of total costs, Table 5).
When caregiver costs (time- and healthcare-related) were included, mean annual costs increased to $US24 969 per patient in the donepezil group and $US26 066 in the placebo group.
From the societal perspective, overall mean (SE) costs increased in all treatment groups to €6,574€32121) for tiotropium, €6,125 (€541) for salmeterol and €5,545€72020) for ipratropium.
Mean monthly medication costs increased with higher baseline phosphate, while mean monthly hospitalisation costs were not clearly associated with phosphate levels.
